Heron Therapeutics is trading at $0.34, up 10.46%, with no specific September 30 catalyst identified. - Shares rose from the September 29 close of $0.31. - The broader market is higher: the S&P 500 is up 0.61% and Nasdaq is up 1.03%, which may support the gain. - A multi-product development and license agreement with Long Grove and Capstone was reported September 29, granting U.S. marketing rights for certain products; available coverage does not establish it as the direct cause of this session’s move.